WO2004054619A1 - 遮光剤及び皮膜組成物 - Google Patents
遮光剤及び皮膜組成物 Download PDFInfo
- Publication number
- WO2004054619A1 WO2004054619A1 PCT/JP2003/016100 JP0316100W WO2004054619A1 WO 2004054619 A1 WO2004054619 A1 WO 2004054619A1 JP 0316100 W JP0316100 W JP 0316100W WO 2004054619 A1 WO2004054619 A1 WO 2004054619A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calcium
- coating
- light
- film
- coating composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to a novel light-shielding agent, a film composition and a novel light-blocking agent capable of suppressing the peeling or whitening phenomenon of a film layer on the surface of a preparation due to light or ultraviolet rays and maintaining the stability and quality of a pharmaceutical preparation or the like for a long period of time.
- Formulations used ⁇ Capsules.
- Some components of pharmaceuticals or health foods, foods and cosmetics are unstable to light, oxygen, and moisture (humidity), and have an unpleasant odor, bitterness, or irritation. Therefore, for the purpose of securing stability or masking them, these problems have been solved by coating with a coating composition containing a light-shielding agent.
- a coating composition containing a light-shielding agent Various types of light-shielding agents are used, but titanium oxide is the most commonly used, and has been used for a long time in the pharmaceutical and cosmetic fields because of its high safety.
- the stability is impaired by titanium oxide, or the decomposition of components is accelerated by radicals generated from titanium oxide by ultraviolet rays, maintaining product quality. Can not do, etc.
- the preparation coated with the titanium oxide-containing coating composition may cause peeling or whitening of the coating over time due to irradiation with light (ultraviolet light).
- light ultraviolet light
- it becomes difficult to maintain the coating state the appearance is impaired, or the components inside are decomposed by light, oxygen, and moisture, and as a result, the effects expected in pharmaceutical preparations and the like are not exhibited. There is concern.
- an object of the present invention is to suppress the peeling or whitening phenomenon of the preparation surface due to light or ultraviolet rays, improve the glossiness of the preparation surface, maintain the appearance for a long time, and stabilize the pharmaceutical preparation etc.
- the present invention provides a light-shielding agent, a film composition, and a preparation / capsule using the same, which can maintain quality and quality for a long time.
- the present inventors have conducted intensive studies and studied and as a result, it has been found that the use of a calcium-containing compound as a novel light-shielding agent can maintain the stability and quality of pharmaceutical preparations and the like for a long period of time, It has been found that a preparation in which peeling and whitening of the preparation surface are suppressed can be obtained. Further, they have found that a coating composition comprising a calcium-containing compound and a coating base can provide the same effects as described above.
- the calcium-containing compound means a calcium salt, calcium hydroxide, calcium oxide, calcium complex such as dolomite or hydroxyapatite, and other compounds containing a calcium element.
- the first invention of the present invention provides a light-shielding agent containing a calcium-containing compound.
- the second invention of the present invention also provides a coating composition containing a calcium-containing compound and a coating base. Further, the third invention of the present invention provides a preparation coated with the above-mentioned light-shielding agent or the above-mentioned film composition containing a calcium-containing compound.
- a fourth invention of the present invention provides a capsule containing the coating composition according to the second invention.
- the light-shielding agent according to the present invention contains one or more calcium-containing compounds.
- the calcium-containing compound used in the present invention a calcium salt, hydroxide Cal Shiumu, calcium oxide and calcium complexes (e.g. dolomite (C a M g (C 0 3) 2) or hydroxyapatite (C a 1 0 (P_ ⁇ 4 ) 6 (OH) 2 ))).
- Ryukko Liyukko is used as a crude drug in a fossil of an ancient large vertebrate skeleton
- Secco II used as a crude drug in natural hydrous calcium sulfate
- a composition containing a calcium-containing compound derived from a natural product such as bovine bone meal, fish bone meal, shell powder, eggshell and the like, and a baked product of these compositions can be used as they are or after purification.
- the calcium-containing compound used in the present invention it is preferable to use at least one selected from the group consisting of calcium salts, hydroxides and calcium oxides, and it is particularly preferable to use calcium salts.
- any of an inorganic calcium salt and an organic calcium salt can be used. There is no particular limitation as long as it is almost dissolved in the solution containing the base, but a water-soluble one is more preferable.
- Examples of the inorganic calcium salt used in the present invention include calcium fluoride, calcium chloride, calcium bromide, calcium carbonate, calcium hydrogen carbonate, calcium phosphate, calcium hydrogen phosphate, calcium hydrogen phosphate, and dihydrogen phosphate. Hydrogen calcium, calcium silicate, calcium sulfate, calcium hydrogen sulfate and calcium nitrate Calcium chloride, calcium phosphate, calcium sulfate, and calcium nitrate are preferred, and calcium chloride is particularly preferred.
- the quality of the inorganic calcium salt is not particularly limited, but the purity is preferably 70% or more, more preferably 80% or more, and particularly preferably 90% or more.
- Examples of the organic calcium salt used in the present invention include calcium acetate, calcium citrate, calcium tartrate, calcium pantothenate, calcium dalconate, calcium succinate, calcium glycerate, calcium saccharate, calcium stearate, and ascorbic acid.
- Calcium, calcium lactate and the like can be mentioned, but calcium lactate and calcium dalconate are particularly preferred.
- the sugar acid refers to a carboxylic acid obtained by formal oxidation of aldehyde group from aldose
- the calcium sugar salt refers to a calcium salt of the sugar acid.
- the quality of the organic calcium salt is not particularly limited, but the purity is preferably 70% or more, more preferably 80% or more, and particularly preferably 90% or more.
- the film composition of the second invention of the present invention comprises one or more of such calcium-containing compounds and one or more film bases.
- the film composition according to the second invention of the present invention has a good film-forming property, a film that is tough and flexible, is harmless to the human body, has no odor, and is chemically inert. It has the advantages of maintaining the general properties required for a product and suppressing peeling and whitening of the coating layer on the surface of the drug product.
- the coating composition of the present invention may be added to a solvent if the calcium-containing compound and the coating base are both dissolved in a homogeneous solvent (for example, if the calcium-containing compound and the coating base are both water-soluble).
- the coating composition is in a solution state instead of a suspension state, so that preparation is easy, it is possible to avoid troubles in the coating process, and at the time of coating. Excellent workability. Also, a white film with excellent gloss can be formed without adding any special additives.
- the film base used in the present invention is not particularly limited, but generally known ones are usually used.
- water-soluble film base methylcellulose, ethylcell mouth
- Cellulose-based polymers such as cellulose, methylhydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose, polyvinylaceta-l-ethylethylaminoacetate, and aminoalkyl methacrylate copolymer E (Eudragit E (trade name) ), Rohm Pharma Co., Ltd., synthetic polymers such as polyvinylpyrrolidone, pullulan, carrageenan (high-molecular-weight polysaccharide for thickening gels extracted from seaweed (Rhodophyta)), hemirose (contained in plants) Polysaccharides), polysaccharides such as arginic acid and mannitol, disaccharides such as sucrose, monosaccharides such as glucose, sugar alcohols such as sorbitol
- the saccharide is a general term for monosaccharides, disaccharides, and polysaccharides in carbohydrates, and the polysaccharides include cellulosic polymers.
- the content of the calcium salt or the like in the coating composition is preferably 0.1 to 150% by mass, more preferably 0.5 to 100% by mass, and particularly preferably 1 to 75% by mass with respect to the film base. . If it is less than 0.1% by mass, the effect of containing calcium or the like is not always sufficient, and if it exceeds 150%, the amount of calcium or the like is too large and the synergistic effect with the base material is not always sufficiently exhibited.
- the film composition of the present invention basically comprises a light-shielding agent and a film base, but may contain various additives as necessary.
- various additives include a plasticizer; polyethylene glycol, propylene glycol, glycerin, Triacetin, medium chain fatty acid triglyceride Perfume, acetyl glycerin fatty acid ester, triethyl citrate, and the like; and other commonly used additives such as lemon oil, orange, d1- or 1-menthol.
- the exfoliation or whitening phenomenon of the preparation surface due to light or ultraviolet rays is suppressed, the glossiness of the preparation surface is improved, and the appearance is maintained for a long time. It is possible to obtain a light-shielding agent, a film composition, and a preparation / capsule using the same, which can maintain the stability and quality of a pharmaceutical preparation or the like for a long time.
- a coloring agent can be added to these four as required, and a generally known coloring agent can be used. Examples of the coloring agent include iron oxide, / 3-carotene, chlorophyll, and aqueous solution. Edible tar dyes and yellow No. 4 aluminum lake.
- a radical scavenger may be appropriately added to the coating composition as needed.
- the radical scavenger to be used is not particularly limited, but a generally known one can be used.
- ⁇ -potency rotin, vitamin C; sodium ascorbate, calcium ascorbate, etc., vitamin ⁇ ; d- ⁇ -tocopherol, d1- ⁇ -tocopherol acetate, etc. sulfite; sodium bisulfite, potassium bisulfite Pum, sodium sulfite, potassium sulfite, sodium metabisulfite, and the like; amino acids; cysteine, and the like, which can be used in appropriate combination.
- novel light-shielding agent of the first invention of the present invention may be in any form such as powder, granule, solid, dispersed liquid, and solution.
- the film composition of the second invention of the present invention may be in any form such as powder, granule, solid, dispersed liquid, and solution.
- the method for producing the coating composition of the second invention of the present invention is not particularly limited, but it can be produced by a generally known method. For example, it is manufactured by adding a potassium-containing compound and a film base and, if necessary, an additive, followed by mixing, or by adding to a solvent and removing the solvent as necessary. can do.
- Solvents used in the production include water or organic solvents such as alcohols such as methyl alcohol and ethyl alcohol, ethers such as dimethyl ether and getyl ether, and ketones such as acetone. Examples thereof include a solvent and a mixture thereof, and preferably, water, methyl alcohol, ethyl alcohol and a mixture thereof.
- the method of coating the preparation with the light-shielding agent or the coating composition of the present invention is not particularly limited, but it can be usually coated by a generally known method.
- a spray coating method, a pan coating method, a tumbling coating method and the like can be mentioned, and a spray coating method is particularly preferable.
- the spray coating method means, for example, using a coating solution in which a potassium-containing compound and a film base are dissolved in water, and using a coating device such as Ikko Yuichi, Flowco Yoichi, etc.) This is a method of spraying, drying and coating tablets and granules.
- the dosage form of the preparation of the present invention includes, for example, tablets, pills, powders, granules, fine granules, capsules and the like, and tablets and granules are particularly preferable.
- examples of the capsule used in the present invention include hard capsules and soft capsules, and hard capsules are particularly preferable.
- the amount of the coating composition used can be determined according to these dosage forms.
- a tablet may be coated at 3 to 15% by weight based on the weight of the tablet.
- These preparations may contain, as necessary, active ingredients such as pharmaceuticals, cosmetics, and health foods, as well as excipients, binders, lubricants, disintegrants, flavoring agents, preservatives, fragrances, coloring agents, etc. Common additives such as adsorbents, wetting agents and disintegration retardants can be added.
- a capsule obtained by coating a preparation with a light-shielding agent or a film composition is filled in the capsule, and the capsule itself may contain the film composition according to the present invention.
- the capsule itself since the capsule itself has a light-shielding property, as a result, effects such as the stability and quality of the formulation inside the capsule can be maintained for a long period of time can be obtained.
- hydroxypropylmethylcellulose HPMC
- purified water 15 to 30 parts by weight of hydroxypropylmethylcellulose (HPMC) is dissolved in purified water while stirring, and 4 to 10 parts by weight of calcium lactate is added to prepare a colorless and transparent immersion liquid. Soak the stainless steel molding pin. Then, the molding pin can be dried while rotating, and the HPMC portion attached to the molding pin can be cut to produce the pin.
- HPMC hydroxypropylmethylcellulose
- the light-shielding agent according to the embodiment of the present invention contains a calcium-containing compound such as a calcium salt
- the film composition according to the embodiment of the present invention contains a calcium-containing compound and a film base exemplified by a cellulosic polymer.
- the preparation according to the embodiment of the present invention is coated with the above-mentioned light-shielding agent or film composition, and the capsule according to the embodiment of the present invention contains the above-mentioned film composition.
- a plasticizer, a fragrance and the like are appropriately added, and in the preparation according to the present invention, a general additive such as an excipient is appropriately added. Have been.
- the light-shielding agent, the coating composition, and the preparation or capsule using one or both of them according to the present invention can suppress the peeling or whitening phenomenon of the preparation surface due to light or ultraviolet rays. It can improve the gloss of the preparation surface, maintain its appearance for a long time, maintain good disintegration, and improve the stability and quality of pharmaceutical preparations, especially light, oxygen, moisture (humidity) ) Can be maintained for a long period of time.
- the film composition of the present invention can be obtained by adding Unlike the titanium oxide-containing coating composition of the prior art, it is not in suspension but in solution, so it is easy to prepare, it is possible to avoid troubles in the coating process, and work during coating Excellent in sex.
- a white film with excellent gloss can be formed without adding any special additives.
- Calcium lactate was added to an 8% by mass aqueous solution of hydroxypropylmethyl cell mouth (HPMC; manufactured by Shin-Etsu Chemical Co., Ltd.) to prepare a clear colorless mixed solution of 0.1 to 6% by mass of calcium lactate. This solution was cast on a glass plate and dried at 60 ° C. for 10 hours to produce a 0.1 mm thick film. The color tone and glossiness of these films were visually observed. Table 1 shows the results. The case without calcium lactate is described as a control. did. Calcium chloride, calcium dalconate, and magnesium chloride were added to an 8% by mass aqueous HPMC solution to prepare a 2% by mass clear colorless mixed solution, and a casting film was produced in the same manner. The color tone and gloss of these films were visually observed. Table 2 shows the results.
- HPMC hydroxypropylmethyl cell mouth
- This coating solution was spray-coated on two phedipine tablets using Doriaco. Ichiichi (DRC-200, manufactured by PAREC) to produce white film tablets having a coating amount of 8%.
- DRC-200 Doriaco. Ichiichi
- 160 g of HPMC was dissolved in 1780 g of purified water, and 40 g of titanium oxide and 20 g of PEG6000 were added to prepare a white suspension coating solution.
- a white film tablet of difedipin (coating amount: 8%) was similarly produced. The color tone and glossiness of these films were visually observed. Table 3 shows the results.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03780782A EP1574220A4 (en) | 2002-12-17 | 2003-12-16 | LIGHT BLOCKING MEDIUM AND FILM COMPOSITION COMPOSITION |
AU2003289356A AU2003289356A1 (en) | 2002-12-17 | 2003-12-16 | Light-blocking agent and film-forming composition |
CA002509620A CA2509620A1 (en) | 2002-12-17 | 2003-12-16 | Light-shielding agent and film-forming composition |
JP2005502493A JP3759949B2 (ja) | 2002-12-17 | 2003-12-16 | 遮光剤及び皮膜組成物 |
US10/539,021 US20060118003A1 (en) | 2002-12-17 | 2003-12-16 | Light-blocking agent and film-forming composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-365323 | 2002-12-17 | ||
JP2002365323 | 2002-12-17 | ||
JP2003-185232 | 2003-06-27 | ||
JP2003185232 | 2003-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004054619A1 true WO2004054619A1 (ja) | 2004-07-01 |
Family
ID=32599272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/016100 WO2004054619A1 (ja) | 2002-12-17 | 2003-12-16 | 遮光剤及び皮膜組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060118003A1 (ja) |
EP (1) | EP1574220A4 (ja) |
JP (1) | JP3759949B2 (ja) |
AU (1) | AU2003289356A1 (ja) |
CA (1) | CA2509620A1 (ja) |
WO (1) | WO2004054619A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008156027A1 (ja) * | 2007-06-20 | 2008-12-24 | Qualicaps Co., Ltd. | 非透明皮膜組成物 |
JP2015124195A (ja) * | 2013-12-27 | 2015-07-06 | 株式会社三和化学研究所 | ミグリトール含有コーティング製剤 |
WO2020009142A1 (ja) | 2018-07-04 | 2020-01-09 | キャプシュゲル・ベルジウム・エヌ・ヴィ | 白色化剤として界面活性剤又は界面活性剤と塩を含有する皮膜形成性組成物 |
WO2020249672A1 (en) | 2019-06-12 | 2020-12-17 | Capsugel Belgium Nv | Film, capsule and film-forming composition comprising water-soluble salt as opacifying agent |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2008081835A1 (ja) * | 2006-12-28 | 2010-04-30 | クオリカプス株式会社 | 水濡れインジケーターおよびタイムインジケーター |
ES2903149T3 (es) * | 2012-05-14 | 2022-03-31 | Shionogi & Co | Preparación que contiene derivado de 7-carbamoilmorfinano 6,7-insaturado |
KR20180062063A (ko) * | 2016-11-30 | 2018-06-08 | (주) 메티메디제약 | 서방형 항암용 약학 조성물 |
CN116440096A (zh) | 2018-05-14 | 2023-07-18 | 比利时胶囊公司 | 含遮光剂的胶囊 |
WO2020161771A1 (ja) * | 2019-02-04 | 2020-08-13 | マルホ株式会社 | 皮膚用組成物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04235914A (ja) * | 1991-01-18 | 1992-08-25 | Kyowa Hakko Kogyo Co Ltd | 徐放性製剤 |
WO2001040182A2 (en) * | 1999-11-30 | 2001-06-07 | Dainippon Pharmaceutical Co., Ltd. | Solid pharmaceutical preparation |
US20020044970A1 (en) * | 2000-08-31 | 2002-04-18 | Toshio Takeuchi | Monolayer sugar-coated tablet and process for preparation thereof |
JP2002365323A (ja) | 2001-04-05 | 2002-12-18 | Denki Kagaku Kogyo Kk | 剥離帯電量測定装置 |
WO2002100381A1 (en) * | 2001-06-07 | 2002-12-19 | Tanabe Seiyaku Co., Ltd. | Functional grain-containing preparations quickly disintegrated in the oral cavity |
JP2003185232A (ja) | 2001-10-12 | 2003-07-03 | Hitachi Building Systems Co Ltd | 空気調和装置用熱源機の管理装置及び管理方法 |
JP2003300872A (ja) * | 2002-04-11 | 2003-10-21 | Ss Pharmaceut Co Ltd | 被覆固形催眠製剤 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB638630A (en) * | 1947-01-08 | 1950-06-14 | Milton Antiseptic Ltd | Improvements in and relating to antisunburn preparations |
GB762700A (en) * | 1954-05-17 | 1956-12-05 | Alginate Ind Ltd | Improvements in or relating to encapsulation |
NL255509A (ja) * | 1959-09-02 | |||
NL262463A (ja) * | 1960-03-21 | |||
JPS4837815B1 (ja) * | 1970-09-25 | 1973-11-14 | Yamanouchi Pharma Co Ltd | |
JPS54105223A (en) * | 1977-12-29 | 1979-08-18 | Yamanouchi Pharmaceut Co Ltd | Coating agent for solid medicine |
JPS5692968A (en) * | 1979-12-26 | 1981-07-28 | Takeji Uchida | Coating composition and resin film capable of preventing damage by ultraviolet light |
JPS605568B2 (ja) * | 1980-09-12 | 1985-02-12 | 帝三製薬株式会社 | 光不安定性薬物を包容するための軟カプセル及びその製造法 |
JP2759802B2 (ja) * | 1988-08-31 | 1998-05-28 | 山之内製薬株式会社 | 薬剤被覆用材料 |
US5411746A (en) * | 1993-02-24 | 1995-05-02 | Warner-Jenkinson Company, Inc. | Dye compositions and methods for film coating tablets and the like |
JPH0834727A (ja) * | 1994-07-25 | 1996-02-06 | Kureha Chem Ind Co Ltd | 被覆軟カプセル |
JPH09272815A (ja) * | 1996-04-02 | 1997-10-21 | Merck Japan Kk | 金属酸化物複合微粒子及びその製造方法 |
AU6521300A (en) * | 1999-10-29 | 2001-05-14 | Fmc Corporation | Edible coating composition |
US7220430B2 (en) * | 2000-01-27 | 2007-05-22 | Tanabe Seiyaku Co., Ltd. | Sustained-release preparation and process for producing the same |
KR100379674B1 (ko) * | 2000-03-06 | 2003-04-10 | 주식회사 서흥캅셀 | 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법 |
US20040137156A1 (en) * | 2002-07-25 | 2004-07-15 | Lee Ernest J | Coated solid dosage form and method for preparing same |
-
2003
- 2003-12-16 WO PCT/JP2003/016100 patent/WO2004054619A1/ja active Application Filing
- 2003-12-16 US US10/539,021 patent/US20060118003A1/en not_active Abandoned
- 2003-12-16 AU AU2003289356A patent/AU2003289356A1/en not_active Abandoned
- 2003-12-16 JP JP2005502493A patent/JP3759949B2/ja not_active Expired - Fee Related
- 2003-12-16 EP EP03780782A patent/EP1574220A4/en not_active Withdrawn
- 2003-12-16 CA CA002509620A patent/CA2509620A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04235914A (ja) * | 1991-01-18 | 1992-08-25 | Kyowa Hakko Kogyo Co Ltd | 徐放性製剤 |
WO2001040182A2 (en) * | 1999-11-30 | 2001-06-07 | Dainippon Pharmaceutical Co., Ltd. | Solid pharmaceutical preparation |
US20020044970A1 (en) * | 2000-08-31 | 2002-04-18 | Toshio Takeuchi | Monolayer sugar-coated tablet and process for preparation thereof |
JP2002365323A (ja) | 2001-04-05 | 2002-12-18 | Denki Kagaku Kogyo Kk | 剥離帯電量測定装置 |
WO2002100381A1 (en) * | 2001-06-07 | 2002-12-19 | Tanabe Seiyaku Co., Ltd. | Functional grain-containing preparations quickly disintegrated in the oral cavity |
JP2003185232A (ja) | 2001-10-12 | 2003-07-03 | Hitachi Building Systems Co Ltd | 空気調和装置用熱源機の管理装置及び管理方法 |
JP2003300872A (ja) * | 2002-04-11 | 2003-10-21 | Ss Pharmaceut Co Ltd | 被覆固形催眠製剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1574220A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008156027A1 (ja) * | 2007-06-20 | 2008-12-24 | Qualicaps Co., Ltd. | 非透明皮膜組成物 |
JP2015124195A (ja) * | 2013-12-27 | 2015-07-06 | 株式会社三和化学研究所 | ミグリトール含有コーティング製剤 |
WO2020009142A1 (ja) | 2018-07-04 | 2020-01-09 | キャプシュゲル・ベルジウム・エヌ・ヴィ | 白色化剤として界面活性剤又は界面活性剤と塩を含有する皮膜形成性組成物 |
KR20210028674A (ko) | 2018-07-04 | 2021-03-12 | 캡슈겔 벨지엄 엔브이 | 백색화제로서 계면 활성제 또는 계면 활성제와 염을 함유하는 피막 형성성 조성물 |
US11801205B2 (en) | 2018-07-04 | 2023-10-31 | Capsugel Belgium Nv | Film-forming composition containing surfactant or surfactant and salt as whitening agent |
WO2020249672A1 (en) | 2019-06-12 | 2020-12-17 | Capsugel Belgium Nv | Film, capsule and film-forming composition comprising water-soluble salt as opacifying agent |
Also Published As
Publication number | Publication date |
---|---|
EP1574220A4 (en) | 2006-01-18 |
JPWO2004054619A1 (ja) | 2006-04-20 |
EP1574220A1 (en) | 2005-09-14 |
CA2509620A1 (en) | 2004-07-01 |
AU2003289356A1 (en) | 2004-07-09 |
JP3759949B2 (ja) | 2006-03-29 |
US20060118003A1 (en) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5677391B2 (ja) | 光安定性に優れた医薬製剤 | |
ES2424492T3 (es) | Composición pulverulenta o granulada que comprende un copolímero, una sal de un ácido monocarboxílico graso y un ácido monocarboxílico graso y/o un alcohol graso | |
FR2900823A1 (fr) | Nouvelle forme d'administration du racecadotril. | |
WO2011081199A1 (ja) | 品質が向上した経口剤 | |
JP5697668B2 (ja) | 口腔内崩壊錠剤 | |
JP3759949B2 (ja) | 遮光剤及び皮膜組成物 | |
JP2008127349A (ja) | 固形組成物 | |
CA2904416A1 (en) | Stabilization of moisture-sensitive drugs | |
WO2005097618A2 (en) | Low dose therapy for treating viral infections | |
TWI286072B (en) | Sleeping medicine formed by coating solid | |
JP2015054851A (ja) | 被覆経口固形製剤 | |
JP4681713B2 (ja) | フィルムコーティング組成物およびそれを用いた防臭性固形製剤 | |
JP4963846B2 (ja) | 口腔内崩壊錠及びその製造方法 | |
KR20120086689A (ko) | 변색 및 냄새가 억제된 필름 코팅정 | |
JP2008127350A (ja) | 臭いを防止した固形組成物 | |
CA3013429A1 (en) | Prolonged release pharmaceutical composition comprising cysteamine or salt thereof | |
WO2011040195A1 (ja) | 不快味マスキング粒子及びこれを含有する経口製剤 | |
JPH037220A (ja) | アルキルシステインまたはその酸付加塩を含有する安定な錠剤 | |
EP3977865A1 (en) | Sodium excretion particles | |
TWI392505B (zh) | 固形組合物 | |
RU2188019C1 (ru) | Фармацевтическая композиция, обладающая противогрибковой активностью, и способ ее получения | |
JP2022144779A (ja) | 被覆固形医薬製剤 | |
JP6150564B2 (ja) | 口腔内速崩壊性錠剤 | |
JP2020023486A (ja) | 組成物 | |
JP2019052101A (ja) | 多層被覆製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2005502493 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2509620 Country of ref document: CA Ref document number: 2003780782 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003780782 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006118003 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10539021 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10539021 Country of ref document: US |